MX9704103A - Composicion farmaceutica que comprende lamotrigina. - Google Patents

Composicion farmaceutica que comprende lamotrigina.

Info

Publication number
MX9704103A
MX9704103A MX9704103A MX9704103A MX9704103A MX 9704103 A MX9704103 A MX 9704103A MX 9704103 A MX9704103 A MX 9704103A MX 9704103 A MX9704103 A MX 9704103A MX 9704103 A MX9704103 A MX 9704103A
Authority
MX
Mexico
Prior art keywords
percent
weight
granules
lamotrigine
pharmacopoeia
Prior art date
Application number
MX9704103A
Other languages
English (en)
Other versions
MXPA97004103A (es
Inventor
Simon Philip Hiskett
Susan Ann Taylor
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MX9704103A publication Critical patent/MX9704103A/es
Publication of MXPA97004103A publication Critical patent/MXPA97004103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una formulacion farmacéutica que comprende (a) de 0.5 a 50% en peso de lamotrigina o una sal de adicion de ácidos de la misma farmacéuticamente aceptable, (b) de 15 a 50% en peso de lactosa, (c) de 15 a 50% en peso de almidon, (d) de 0.5 a 15% en peso de celulosa cristalina, y (e) de 5 a 15% en peso de polivinilpirrolidona, y la cual está en la forma de un polvo que fluye libremente de gránulos que tienen las siguientes propiedades: (i) los gránulos no tienen un tamaño de partícula mayor que 850æm, (ii) al menos 90% en peso de los gránulos tienen un tamaño de partícula de 75 a 850æm, (iii) los gránulos se desintegran en 30 minutos de acuerdo a la Prueba de Desintegracion de The Pharmacopoeia of Japan, duodécima edicion, 1991, y (iv) al menos 90% en peso de la lamotrigina o sal de lamotrigina en los gránulos se disuelven dentro de 30 minutos cuando los gránulos se someten a la Prueba de Disolucion, método 2 (método con rueda de paletas) de The Pharmacopoeia of Japan, duodécima edicion, 1991.
MXPA/A/1997/004103A 1994-12-07 1997-06-03 Composicion farmaceutica que comprende lamotrigina MXPA97004103A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9424766.5 1994-12-07
GBGB9424766.5A GB9424766D0 (en) 1994-12-07 1994-12-07 Pharmaceutical composition
GB94247665 1994-12-07
PCT/GB1995/002865 WO1996017611A1 (en) 1994-12-07 1995-12-07 Pharmaceutical composition comprising lamotrigine

Publications (2)

Publication Number Publication Date
MX9704103A true MX9704103A (es) 1997-09-30
MXPA97004103A MXPA97004103A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
JP2977284B2 (ja) 1999-11-15
NZ296573A (en) 1997-08-22
ES2172600T3 (es) 2002-10-01
NO972623L (no) 1997-08-06
WO1996017611A1 (en) 1996-06-13
BR9509975A (pt) 1998-06-09
PL320560A1 (en) 1997-10-13
FI972434A (fi) 1997-06-09
EP0797441A1 (en) 1997-10-01
GB9424766D0 (en) 1995-02-08
NO972623D0 (no) 1997-06-06
AU696406B2 (en) 1998-09-10
AU4121196A (en) 1996-06-26
CZ171797A3 (en) 1997-11-12
CA2207284A1 (en) 1996-06-13
FI972434A0 (fi) 1997-06-06
HUT77367A (hu) 1998-03-30
ATE213633T1 (de) 2002-03-15
US5861179A (en) 1999-01-19
CN1174505A (zh) 1998-02-25
DE69525649T2 (de) 2002-09-05
DE69525649D1 (de) 2002-04-04
EP0797441B1 (en) 2002-02-27
RU2160106C2 (ru) 2000-12-10
JPH10510255A (ja) 1998-10-06

Similar Documents

Publication Publication Date Title
EP1058538B2 (en) Fast disintegrating tablets
AU755616B2 (en) Stabilization of compositions containing ace inhibitors using magnesium oxide
KR100384264B1 (ko) 습식과립화에의한 투여단위의제조방법
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
AU1531199A (en) Pharmaceutical suspension tablet compositions
CA2330480A1 (en) Controlled release formulation of divalproex sodium
CA2265766A1 (en) Rapidly disintegrating pellets
EP0274845B1 (en) Stable solid pharmaceutical composition containing ibuprofen and codeine
SK5672001A3 (en) Improved fast disintegrating tablet
CA2008972A1 (en) Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
CA2046679A1 (en) Pharmaceutical composition for rapid suspension in water
CA2155210A1 (en) Cross-linked amylose as a binder/disintegrant in tablets
HUP0000141A2 (hu) Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására
RU97111870A (ru) Фармацевтический состав, содержащий ламотригин
CA2342634A1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
SK119799A3 (en) Swallow tablet comprising paracetamol
US3865935A (en) Tableting of erythromycin base
US5087454A (en) Ibuprofen tablet
EP0500851A1 (en) METHOD FOR PRODUCING AN ACTIVE SUBSTANCE SENSITIVE TO HEAT, LIGHT AND MOISTURE, WITH A TABLET OR DRAGED COMPOSITION CONTAINING CRYSTALLINE STRUCTURE.
US6555135B1 (en) Pharmaceutical compositions comprising co-micronized fenofibrate
JP2009091362A6 (ja) 高含量ファムシクロビル錠剤
JP2009091362A (ja) 高含量ファムシクロビル錠剤
AU1515595A (en) Method for preparing low dose pharmaceutical products
MX9704103A (es) Composicion farmaceutica que comprende lamotrigina.
PT95304A (pt) Processo para a preparacao de uma composicao de acetominofeno

Legal Events

Date Code Title Description
FA Abandonment or withdrawal